Key points are not available for this paper at this time.
This commentary argues that while cutaneous adverse effects are associated with better outcomes among patients undergoing treatment with pembrolizumab, further analysis is required to determine whether nonvitiligo cutaneous adverse effects contribute to the observed outcome.
Lo et al. (Thu,) studied this question.